Drugs News and Research

RSS

Genentech, Seragon, Regeneron and Avalanche receive Allicense 2015 Breakthrough Award for Deals of the Year

The Intellectual Property and Science business of Thomson Reuters, the world's leading provider of intelligent information for businesses and professionals, recently honored Genentech Partnering and Seragon, and Regeneron and Avalanche with the Allicense 2015 Breakthrough Award for Deals of the Year.

3 Jun 2015

Manchester, UCL researchers discover new technique for treating polycystic kidney disease

A new technique for treating polycystic kidney disease has been identified by researchers at The University of Manchester and UCL.

3 Jun 2015

Ultrasound becoming the most widely used imaging tool in medicine today

Mention "ultrasound" and most people likely will think of an image of a fetus in a mother's womb. But while providing peeks at the not-yet-born is one of ultrasound's most common applications, that's only a small part of the picture.

3 Jun 2015

McMaster University researchers identify key protein required to maintain muscle strength during aging

What causes us to lose muscle strength as we age and how exercise can prevent it from happening has never been thoroughly understood, but McMaster University researchers have discovered a key protein required to maintain muscle mass and muscle strength during aging.

3 Jun 2015

Use of antidepressants in late pregnancy may be associated with increased risk of PPHN

An analysis of approximately 3.8 million pregnancies finds that use of antidepressants late in pregnancy may be associated with an increased risk of persistent pulmonary hypertension of the newborn (PPHN), according to a study in the June 2 issue of JAMA. However, the absolute risk was small and the risk increase appears more modest than suggested in previous studies.

3 Jun 2015

Women who suffer from fibromyalgia benefit from hyperbaric oxygen therapy

Women who suffer from fibromyalgia benefit from a treatment regimen in a hyperbaric oxygen chamber, according to researchers at Rice University and institutes in Israel.

3 Jun 2015

Using graphene as alternative coating for catheters to improve chemotherapy delivery

A new study published in IOP Publishing's journal 2D Materials has proposed using graphene as an alternative coating for catheters to improve the delivery of chemotherapy drugs.

3 Jun 2015

WHO accepts Elafibranor as generic name for GENFIT’s GFT505 drug candidate

GENFIT, a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, today announces that the World Health Organization (WHO) has accepted the international non-proprietary name (INN, or generic name) Elafibranor for its leading drug candidate previously referred to as GFT505.

3 Jun 2015

Researchers transform bacteria into 'secret agents' for detecting disease

Another step forward has just been taken in the area of synthetic biology. Research teams from Inserm and CNRS (French National Centre for Scientific Research) Montpellier, in association with Montpellier Regional University Hospital and Stanford University, have transformed bacteria into "secret agents" that can give warning of a disease based solely on the presence of characteristic molecules in the urine or blood. To perform this feat, the researchers inserted the equivalent of a computer programme into the DNA of the bacterial cells.

3 Jun 2015

New study looks at academic outcomes of children following resective epilepsy surgery

A new study by a University of Toronto Mississauga researcher has taken the first-ever look at the academic outcomes of children with epilepsy who have had brain surgery, and found that they have a higher chance of struggling in class following their surgery.

3 Jun 2015

Teens start misusing ADHD drugs and other stimulants earlier than you might think

Despite stereotypes about college students resorting to black-market Ritalin to help them cram for exams, young people are actually most likely to start misusing prescription stimulant drugs in their high school years, according to new University of Michigan Medical School research.

3 Jun 2015

Scientists identify gene mutation that causes color blindness

A rare eye disorder marked by color blindness, light sensitivity, and other vision problems can result from a newly discovered gene mutation identified by an international research team, including scientists from Columbia University Medical Center.

3 Jun 2015

Nivolumab and pembrolizumab therapies continue to show promise against advanced melanomas

Results of two clinical trials reported at the American Society for Clinical Oncology Annual Meeting 2015 show continued promise of immune therapies nivolumab and pembrolizumab against advanced melanomas, specifically in the context of PD1 signaling that some tumors use to avoid immune system attack. Dr. Rene Gonzalez, MD, investigator at the University of Colorado Cancer Center and director of the Melanoma Research Clinics at the CU School of Health, is an author of both studies.

2 Jun 2015

Researchers explore association between SSRI exposure in late pregnancy and risk of PPHN

Use of antidepressants late in pregnancy has been controversial since the FDA issued a Public Health Advisory in 2006 warning that the use of antidepressants in late pregnancy may increase risk of persistent pulmonary hypertension of the newborn (PPHN), a condition that typically occurs in term or near-term infants and presents within hours of birth with severe respiratory failure requiring intubation and mechanical ventilation.

2 Jun 2015

Celltrion receives approval for infliximab biosimilar antibody from Brazil's ANVISA

Hospira, Inc., a global leader in biosimilars, today announced that its partner, Celltrion – a global biopharmaceutical company – has received approval from ANVISA – the National Health Surveillance Agency in Brazil – for Remsima (infliximab), the first biosimilar monoclonal antibody approved for use in Brazil.

2 Jun 2015

MorphoSys' MOR202 proprietary drug candidate meets primary endpoints in multiple myeloma patients

MorphoSys AG today published first safety and efficacy data on its proprietary drug candidate MOR202. The data are from a phase 1/2a study in 42 heavily pretreated patients with relapsed/refractory multiple myeloma.

2 Jun 2015

ASCO 2015: Berg presents data from BPM 31510 Phase Ib trial for solid tumors

Berg, a biopharmaceutical company committed to uncovering health solutions through a data-driven, biological approach, presented clinical research from its trials using its cancer drug BPM 31510 on Phase Ib solid tumors and preclinical data on triple negative breast cancer, at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO), May 29 – June 2 in Chicago.

2 Jun 2015

EMA grants Orphan Drug Designation to Stempeucel for treatment of Thromboangiitis Obliterans

Stempeutics Research, a group company of Manipal Education & Medical Group and a joint venture with Cipla Group, announced today that the European Medicines Agency (EMA) has granted Orphan Drug Designation for its drug Stempeucel® for the treatment of Thromboangiitis Obliterans.

2 Jun 2015

Experimental drug and common antibiotic combination holds promise for pancreatic cancer treatment

Despite surgical advances, pancreatic cancer continues to be one of the most deadly and difficult cancers to manage due to a lack of effective therapies. However, VCU Massey Cancer Center and VCU Institute of Molecular Medicine (VIMM) scientists in the lab of Paul B. Fisher, M.Ph., Ph.D., are hoping to change that with a novel combination of an experimental drug and a common antibiotic that has shown promising results in preclinical experiments.

2 Jun 2015

Intermountain Precision Genomics: Precision medicine can benefit advanced cancer patients without increasing costs

Two new studies conducted by Intermountain Healthcare’s Intermountain Precision Genomics reveal that precision medicine can improve survival in advanced cancer patients – and do so without increasing costs.

2 Jun 2015

Drugs News and Research

Genentech, Seragon, Regeneron and Avalanche receive Allicense 2015 Breakthrough Award for Deals of the Year

Manchester, UCL researchers discover new technique for treating polycystic kidney disease

Ultrasound becoming the most widely used imaging tool in medicine today

McMaster University researchers identify key protein required to maintain muscle strength during aging

Use of antidepressants in late pregnancy may be associated with increased risk of PPHN

Women who suffer from fibromyalgia benefit from hyperbaric oxygen therapy

Using graphene as alternative coating for catheters to improve chemotherapy delivery

WHO accepts Elafibranor as generic name for GENFIT’s GFT505 drug candidate

Researchers transform bacteria into 'secret agents' for detecting disease

New study looks at academic outcomes of children following resective epilepsy surgery

Teens start misusing ADHD drugs and other stimulants earlier than you might think

Scientists identify gene mutation that causes color blindness

Nivolumab and pembrolizumab therapies continue to show promise against advanced melanomas

Researchers explore association between SSRI exposure in late pregnancy and risk of PPHN

Celltrion receives approval for infliximab biosimilar antibody from Brazil's ANVISA

MorphoSys' MOR202 proprietary drug candidate meets primary endpoints in multiple myeloma patients

ASCO 2015: Berg presents data from BPM 31510 Phase Ib trial for solid tumors

EMA grants Orphan Drug Designation to Stempeucel for treatment of Thromboangiitis Obliterans

Experimental drug and common antibiotic combination holds promise for pancreatic cancer treatment

Intermountain Precision Genomics: Precision medicine can benefit advanced cancer patients without increasing costs

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News